

## Review Article

# Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Haiming Fang <sup>1</sup>, Lian Fu,<sup>1</sup> and Jiajia Wang <sup>2</sup>

<sup>1</sup>Department of Gastroenterology and Hepatology, The Second Hospital of Anhui Medical University, Hefei, Anhui Province, China

<sup>2</sup>Department of Pharmacology, Anhui Medical University, Hefei, Anhui Province, China

Correspondence should be addressed to Haiming Fang; [haimingfang@163.com](mailto:haimingfang@163.com) and Jiajia Wang; [38338569@qq.com](mailto:38338569@qq.com)

Received 27 April 2018; Accepted 26 August 2018; Published 13 September 2018

Academic Editor: Gelin Xu

Copyright © 2018 Haiming Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Fecal microbiota transplantation (FMT) is an emerging treatment approach for inflammatory bowel disease (IBD). The donor selection, the separation of fecal bacteria, the frequency of FMT, the way of infusion, the long-term safety, and efficacy are still uncertain. **Aim.** To further study the efficacy and safety and protocol of FMT for IBD. **Methods.** A systematic review and meta-analysis were conducted until February, 2018. Clinical remission was established as the primary outcome. **Results.** A total of 596 paediatric and adult IBD patients were enrolled, and 459 patients received FMT therapy. 28.8% (132/459) patients achieved clinical remission during follow-up. 53% (241/459) patients achieved clinical response. The pooled estimated clinical remission for ulcerative colitis (UC) was 21% (95% CI: 8%-37%) and 30% (95% CI: 11%-52%) for Crohn's disease (CD), both with a risk of heterogeneity; 10% (95% CI: 0%-43%) for paediatric UC; 26% (95% CI: 10%-48%) for adult UC; 45% for paediatric CD (95% CI: 24%-66%); 22% (95% CI: 3%-52%) for adult CD. Meta-analysis of cohort studies showed that moderate-severe IBD patients could achieve more significant remission from FMT than mild-moderate patients ( $P=0.037$ ). Delivery route has no impact on the efficacy of FMT in UC and CD. Based on current available evidence, a trend was observed towards higher clinical remission rate of frozen stool FMT than that of fresh stool for UC, while there was no significant difference between fresh and frozen FMT for CD. The optimal donor stool for FMT is still uncertain. Meta-analysis of RCTs showed that FMT treatment achieved significantly higher clinical remission rate than placebo for UC (28% versus 9%,  $P=0.0003$ ). **Conclusion.** FMT is an effective and safe therapy for both paediatric and adult IBD; fresh or frozen donor stool, delivery route, and antibiotic pretreatment or not have no impact on the efficacy of FMT in IBD. FMT might be a potential rescue therapy and even an initial standardized therapy for IBD. However, few data exist on long-term safety and efficacy and further validation is needed.

## 1. Introduction

The gut microbiota provides an intestinal biological barrier against pathogens and has a pivotal role in the maintenance of intestinal homeostasis and modulation of the host immune system [1]. Multifaceted microbial population is considered as a human organ with critical function. The specific changes in the composition of gut microbiota, termed dysbiosis, have been associated not only with many gastrointestinal (GI) diseases but also with metabolic diseases, autoimmune diseases, allergic disorders, and neuropsychiatric disorders [2].

Inflammatory bowel disease (IBD) is a chronic relapsing gastrointestinal tract inflammatory disorder, including ulcerative colitis (UC) and Crohn's disease (CD), which is

characterized by progressive transmural inflammation of the gut. Over the past decades, the incidence and prevalence of IBD have gradually increased in Asian countries, including China. Although the etiology of the disease remains unclear, IBD involves interactions among genetic susceptibility, environmental factors (antigens derived from commensal bacteria), intestinal microbiota, and the immune system [3]. Several clinical and preclinical researches have shown that dysbiosis of gut microbiota is associated with IBD, which seems to play a crucial role in the development of this disease [4, 5].

Manipulating the gut microbiota via fecal microbiota transplantation (FMT) is an emerging treatment approach. The concept of FMT was first described in China during 4th

century. Human fecal suspension by mouth was used to treat patients who had food poisoning or severe diarrhea [6]. FMT was reported in 1958 for treating refractory and recurrent *Clostridium difficile* infection (RCDI) [7]. Recent studies have shown that FMT is an effective treatment for RCDI, with greater than 90% success rate and can be considered as an antibiotic replacement for RCDI [8]. Due to the satisfactory effect of FMT for RCDI, the American Society of Gastroenterology, the European Association of Clinical Microbiology, and European Association of Infectious Diseases had listed FMT in the treatment guidelines of RCDI in 2013 and 2014, respectively [9, 10]. This has encouraged researches on FMT as a potential therapy for other microbial-related diseases such as IBD.

Since Bennet [11] reported the first case of FMT for the treatment of UC in 1989, lots of case reports, case series, and, more recently, randomized controlled trials (RCTs) had been reported regarding investigating the efficacy and safety of FMT for IBD. Sun et al. [12] reported that the rate of clinical remission in patients with UC was 30.4%. Shi et al. [13] showed that 41.58% patients with UC achieved clinical remission and 65.28% achieved clinical response. Moayyedi et al. [14] and Paramsothy et al. [15] showed that the rate of clinical remission in patients who received FMT was higher than that of placebo. However, Rossen et al. [16] was not able to demonstrate a significant difference in the rate of clinical remission between the FMT and placebo groups.

Up to date, a number of questions on the protocol of FMT remain unanswered. The donor selection, the separation of fecal bacteria, the frequency of FMT, the way of infusion, the long-term safety, and efficacy are still uncertain. Many reports recommend giving bowel lavage before donor feces infusion and also giving antibiotics before the transplantation to facilitate the colonization of microbiota from the donor [17]. However, whether colonic lavage and/or antibiotic therapy have any impact on FMT for IBD is still uncertain. There is also uncertainty as to whether fresh or frozen fecal samples should be used for FMT in IBD. We performed a systematic review and meta-analysis with the most up-to-date and reliable evidence to assess these questions.

## 2. Materials and Methods

**2.1. Inclusion Criteria.** Studies included in this systematic review must report on clinical efficacy and safety of FMT for IBD in paediatric or adult subjects. Only cohort studies and RCTs were enrolled for meta-analysis. Literature language was limited to Chinese or English.

**2.2. Exclusion Criteria.** Studies were excluded if data were only case reports or case series of FMT for IBD. Studies were also excluded if data had no clear definition of remission or clinical endpoints or they only included patients who had coinfection with *Clostridium difficile* or other pathogens. In addition, systematic review and meta-analyses data were also excluded.

**2.3. Literature Search Strategy.** A systematic review was performed in accordance with the PRISMA [42], Cochrane [43],

and MOOSE [44] guidelines. We searched Medline (from 1948), web of science (from 1926), Cochrane library (for all years), EMBASE (from 1947), CNKI, Wanfang Data, and Pubmed. Study types included randomized controlled trials (RCTs), cohort studies and case studies (case series and case reports), nonrandomized controlled studies, and nonrandomized experimental studies. We also searched proceedings from annual world meetings including European Crohn's and Colitis Organization (ECCO), Digestive Diseases Week (DDW), American College of Gastroenterology (ACG) and Advances in IBD (AIBD), and United European Gastroenterology Week (UEGW) from 1995 to February, 2018. The search key words were "ulcerative colitis" or "UC" or "Crohn disease" or "CD" or "inflammatory bowel diseases" or "IBD" or "adult IBD" or "paediatric IBD" or "child IBD" AND "fecal microbiota transplantation" or "fecal microbiota transfusion" or "stool microbiota transplantation" or "stool microbiota transfusion" or "faecal microbiota transplantation" or "gut flora" or "intestinal flora".

Literature screening, data extraction, and reviewing work were accomplished by two investigators in strict accordance with the inclusion and exclusion criteria. In case of dispute, the key decision was made by the third investigator, who is a famous statistical expert.

**2.4. Study Quality Assessment.** For eligible cohort studies, we used the Newcastle-Ottawa Scale [45] on the standard 9-point scale to assess the methodological quality, including the study population selection, comparability, and outcome evaluation. Thus the study was divided into the following items: the selection of groups (for age, disease severity), ascertainment of FMT treatment and absence of prior exposure to FMT, outcome quality evaluation (predefined disease activity index score or mucosal evaluation), and adequate follow-up time and reports. Follow-up time  $\geq 3$  months was considered to be abundant follow-up; there were three studies indicating no sufficient follow-up reports ( $\geq 1$  month). Through comprehensive analysis and evaluation, the studies quality was moderate to high. The Cochrane risk of bias score was used to assess bias in RCTs [46], incorporating random sequence generation, blinding, allocation concealment, selective reporting, and incomplete outcome data.

**2.5. Statistical Analysis.** Descriptive statistics were performed on data extracted from all included studies. Efficacy of FMT in IBD was evaluated as clinical remission (primary outcome) or clinical response defined by the respective study authors. Safety was assessed using reported adverse event and serious adverse event data. For cohort studies, the pooled proportion of achieving clinical remission rates and subgroup analyses were analyzed using R software. The pooled effect sizes and 95% confidence intervals were obtained using the random effects model. For meta-analyses of RCTs, a random effects model was selected to assess the pooled estimate of clinical remission using Review Manager 5.2 (Nordic Cochrane centre, Copenhagen, Denmark, 2012), the pooled odd ratios (P-ORs) were calculated by weighting individual ORs by the inverse of their variance.  $P$  value  $< 0.05$  was considered statistically significant. The Cochran's Q test ( $P$  value  $< 0.10$ )




FIGURE 1: Literature screening process and flow diagram.

and Higgins' test [ $I^2$ ] (low heterogeneity: <25%, moderate heterogeneity: 25-75%, high heterogeneity: >75%) were used to assess the statistical heterogeneity [47]. To evaluate the stability of our results, sensitivity analyses were performed. Subgroup analyses were performed according to IBD subtype (UC versus CD), preparation of inoculum (fresh versus frozen), population (paediatric versus adult), and route of administration (upper versus lower gastrointestinal tract). Funnel plots and Egger's test were used to assess potential publication biases.

### 3. Results

**3.1. Literature Screening Process.** A total of 5680 articles were identified in the search, which included 3320 records after removing duplicates. Finally a total of 27 articles of FMT for IBD were deemed to satisfy the study selection criteria (as shown in Figure 1) including 23 cohort studies (21 uncontrolled, 2 controlled) and 4 randomized controlled trials (RCTs). A total of 596 IBD patients were enrolled in which 459 patients received FMT therapy, and 132 IBD patients achieved clinical remission during follow-up.

In this system review, both paediatric and adult IBD were included. Age ranged from 7 to 71 years and follow-up time ranged from 1 to 72 months. Severity of disease varied from mild to severe (as shown in Table 1).

**3.2. Meta-Analysis of Cohort Studies.** In strict accordance with the inclusion and exclusion criteria, 23 cohort studies were deemed to satisfy the selection criteria including 15 in UC, 4 in CD, and 4 in both UC and CD with a total of 319 patients (as shown in Table 1), which were all treated with FMT and the efficacy and safety were assessed during the long enough follow-up.

23 cohort studies included 319 IBD patients (225 UC and 94 CD), in which 129 patients had mild or moderate disease, 55 patients moderate-severe, 67 patients "refractory", 36 patients "active disease" and 32 patients were hormone-dependent. Studies included

both adults (252 cases) and paediatric (67 cases) patients. 213 patients were treated with fresh donor stool and 80 patients were treated with frozen stool protocol, and in 26 patients the donor of fecal microbiota was not identified.

FMT was administered via the upper gastrointestinal tract (nasogastric/nasojejunal tube or endoscopic duodenal infusion) in 105 patients, via the lower gastrointestinal tract (enema, colonoscopy or rectal tube) in 157 patients, and via both routes in 57 patients (as shown in Table 1).

Donor stools were mainly from healthy adults or children family members or close friends or volunteers. Among the 319 patients, 134 patients received fecal bacteria from their family members or close friends in which 26 patients (21%, 26/134) achieved clinical remission. 79 patients received fecal bacteria from healthy anonymous donors with 37% (29/79) patients achieving clinical remission, 37 patients received fecal bacteria from family members or friends and healthy volunteers, and 69 patients had no donor source report (as shown in Table 1).

**3.2.1. Pooled Remission and Response of FMT for IBD.** Among the 23 cohort studies, including 319 IBD patients, 93 patients achieved clinical remission; meta-analysis showed that the pooled proportion of clinical remission of FMT in IBD was 27%, with a high heterogeneity (as shown in Table 2 and supplement Figure 1).

**3.2.2. Ulcerative Colitis versus Crohn's Disease.** The 319 patients consisted of 225 UC patients and 94 CD patients. Among the 225 UC patients, 53 cases achieved clinical remission during follow-up; the pooled estimate of clinical remission rate was 21%, with a high risk of heterogeneity after meta-analysis. Among the 94 CD patients, 40 patients achieved clinical remission; the pooled proportion of clinical remission was 30%, with a risk of heterogeneity (as shown in Table 2 and supplement Figure 2). Publications bias was observed in this meta-analysis.

TABLE 1: Characteristics of the included cohort studies of FMT in IBD.

| Study                                 | type  | n        | Age(y) | Severity   | Route                       | Donor  | Fresh/Frozen      | Clinical response | Clinical remission | Follow-up (months) |
|---------------------------------------|-------|----------|--------|--|-----------------------------|--|-------------------|-------------------|--------------------|--------------------|
| Angelberger et al [18] (2013)         | UC    | 5        | 22-51  | moderate-severe  | nasojejunal tube and enema  | identified but first degree relatives excluded | Fresh             | 1                 | 0                  | 3                  |
| Kunde et al [19].(2013)               | UC    | 10       | 7-21   | mild-moderate  | colonoscopy                 | family members or close friends                | Fresh             | 6                 | 3                  | 1                  |
| Kump et al [20].(2013)                | UC    | 6        | 17-52  | moderate-severe  | enema                       | unrelated healthy children                     | Frozen            | 2                 | 0                  | 3                  |
| Cui et al [21] a (2015)               | UC    | 15       | 11-48  | moderate-severe  | gastroscopy                 | (patient relatives or friends)                 | Frozen            | 12                | 4                  | 4-72               |
| Damman et al [22] (2015)              | UC    | 7        | 27-61  | mild-moderate  | colonoscopy                 | family members or close friends                | Fresh             | 1                 | 1                  | 3                  |
| Ren et al [23] (2015)                 | UC    | 7        | 17-66  | severe   | Colonoscopy and gastroscopy | family members or unrelated                    | Fresh             | 7                 | 7                  | 1-7                |
| Scalaferrri et al [24].(2015)         | UC    | 8        | 30-44  | mild-moderate  | colonoscopy                 | unrelated                                      | NR                | 4                 | 3                  | 3                  |
| Wei al et [25] a(2015)                | UC/CD | 14       | 16-70  | mild-moderate  | colonoscopy                 | unrelated                                      | Frozen            | 9                 | 6                  | 1                  |
| Suskind et al [26] a.(2015)           | UC    | 4        | 13-16  | mild-moderate-moderate-severe, refractory, failed immunotherapy and anti-TNF | nasogastric                 | NR   | Fresh             | 0                 | 0                  | 3                  |
| Vermeire et al [27].(2016)            | UC/CD | 14(8/6)  | 28-53  | refractory, failed immunotherapy and anti-TNF                                | Nasojejunal or rectal       | family members or close friends                | Fresh             | 2                 | 2                  | 2                  |
| Nishida et al [28].(2017)             | UC    | 41       |        | mild-moderate  | colonoscopy                 | family members                                 | Fresh             | 11                | 0                  | 2                  |
| Wei et al [29] b (2016)               | UC    | 20       | 18-70  | mild-moderate  | colonoscopy                 | unrelated                                      | Fresh             | 13                | 7                  | 3                  |
| Ishikawa et al [30] (2017)            | UC    | 17       | 21-65  | mild-to-severe active  | colonoscopy                 | family members                                 | Fresh             | 14                | 9                  | 1                  |
| Zhang et al [31] (2016)               | UC    | 19       | 19-60  | moderate-severe  | gastroscopy                 | NR   | Fresh             | 11                | 2                  | ≥3                 |
| Karakan et al [32].(2016)             | UC    | 14       | NR     | Steroid-dependent  | colonoscopy                 | NR   | NR                | 11                | 6                  | 3-18               |
| Goyal et al [33].(2016)               | UC/CD | 16(12/4) | <18    | mild-moderate immunotherapy dependent  | gastroscopy                 | NR   | Fresh             | 5                 | 2                  | 6                  |
| Kellermayer et al [34] (2015)         | UC    | 3        | 14-16  | moderate-severe  | colonoscopy and enema       | unrelated                                      | Frozen            | 3                 | 3                  | 3                  |
| Karolewska-Bochenek et al [35] (2015) | UC    | 4        | 10-17  | mild-moderate  | gastroscopy                 | unrelated                                      | NR                | 4                 | 0                  | 1                  |
| Cui et al [36] b.(2015)               | CD    | 30       | 15-71  | moderate-severe  | gastroscopy                 | family members or close friends or unrelated   | 23 Fresh 7 Frozen | 20                | 18                 | 6-15               |
| Suskind et al [37] b (2015)           | CD    | 9        | 12-19  | mild-moderate  | nasogastric                 | family members(parents)                        | Fresh             | 7                 | 5                  | 3                  |
| Vaughn et al [38].(2016)              | CD    | 19       |        | active   | colonoscopy                 | unrelated                                      |                   | 11                | 10                 | 6.5                |
| Zhang et al [39].(2013)               | CD    | 16       | 14-63  | refractory   | gastroscopy                 | NR   | Frozen            | 12                | 3                  | 1                  |
| Alka-Goyal et al [40].(2018)          | UC/CD | 21(14/7) | 8-21   | refractory   | colonoscopy and gastroscopy | family members or close friends                | Fresh             | 6                 | 2                  | 6                  |

UC: ulcerative colitis; CD: Crohn's disease; NR: no report.

TABLE 2: Prevalence in different subgroups.

| Stratification group                   | Number of studies | Number | Events | $I^2$ | $p$ value | Prevalence | 95% CI    |
|--|-------------------|--------|--------|-------|-----------|------------|-----------|
| Current prevalence                     | 23                | 319    | 93     | 86%   | <0.01     | 0.27       | 0.15-0.41 |
| <b>Subtype</b>                         |                   |        |        |       |           |            |           |
| UC                                     | 19                | 225    | 53     | 88%   | <0.01     | 0.21       | 0.08-0.38 |
| CD                                     | 8                 | 94     | 40     | 75%   | <0.01     | 0.3        | 0.13-0.52 |
| <b>Populations</b>                     |                   |        |        |       |           |            |           |
| Paediatric UC                          | 6                 | 47     | 6      | 85%   | <0.01     | 0.1        | 0.00-0.43 |
| Adult UC                               | 13                | 178    | 45     | 88%   | <0.01     | 0.26       | 0.10-0.48 |
| Paediatric CD                          | 3                 | 20     | 9      | 0%    | 0.53      | 0.45       | 0.24-0.66 |
| Adult CD                               | 5                 | 74     | 31     | 85%   | <0.01     | 0.22       | 0.03-0.52 |
| <b>Preparation of inoculum</b>         |                   |        |        |       |           |            |           |
| Fresh for UC                           | 12                | 164    | 31     | 89%   | <0.01     | 0.15       | 0.03-0.37 |
| Frozen for UC                          | 4                 | 35     | 13     | 87%   | <0.01     | 0.42       | 0.05-0.86 |
| Fresh for CD                           | 5                 | 49     | 24     | 78%   | <0.01     | 0.36       | 0.10-0.68 |
| Frozen for CD                          | 4                 | 45     | 16     | 69%   | 0.02      | 0.28       | 0.07-0.55 |
| <b>Route of administration</b>         |                   |        |        |       |           |            |           |
| Upper GI for UC                        | 4                 | 42     | 6      | 51%   | 0.10      | 0.08       | 0.00-0.26 |
| Lower GI for UC                        | 10                | 137    | 38     | 88%   | <0.01     | 0.31       | 0.11-0.57 |
| Upper GI for CD                        | 5                 | 63     | 26     | 83%   | <0.01     | 0.23       | 0.02-0.55 |
| Lower GI for CD                        | 2                 | 20     | 10     | 60%   | 0.11      | 0.27       | 0.00-0.93 |
| <b>Disease severity</b>                |                   |        |        |       |           |            |           |
| Mild-moderate                          | 9                 | 129    | 27     | 84%   | <0.01     | 0.20       | 0.06-0.41 |
| Moderate-severe                        | 11                | 133    | 45     | 83%   | <0.01     | 0.30       | 0.10-0.54 |
| <b>pre-antibiotic treatment or not</b> |                   |        |        |       |           |            |           |
| Pretreatment                           | 7                 | 85     | 29     | 73%   | <0.01     | 0.25       | 0.09-0.46 |
| Un-pretreatment                        | 16                | 234    | 64     | 89%   | <0.01     | 0.28       | 0.13-0.47 |

3.2.3. *Paediatric versus Adult Populations.* Totally, 67 paediatric IBD (47 UC and 20 CD) and 252 adult IBD (178 UC and 74 CD) were enrolled in the subgroup analysis. 6 patients in 47 paediatric UC achieved clinical remission, and 45 patients in 178 adult UC achieved clinical remission. Meta-analysis showed that the pooled proportion of clinical remission rate of FMT for paediatric UC was 10%, and 26% for adult UC, both with a high risk of heterogeneity (as shown in Table 2).

9 patients in 20 paediatric CD achieved clinical remission and 31 patients in 74 adult CD achieved clinical remission. The pooled estimate of clinical remission rate of FMT for paediatric CD was 45% and 22% for adult CD (as shown in Table 2).

Up to date, no randomized controlled trials were published assessing FMT in paediatric IBD.

3.2.4. *Preparation of Inoculum.* The subgroup analysis of all cohort studies showed that preparation of inoculum and route of administration might play a significant role in clinical remission.

Among the 225 UC patients, 164 patients accepted fresh donor stool FMT in which 31 cases achieved clinical remission, and 35 patients accepted frozen stool FMT in which 13 cases achieved clinical remission. The pooled clinical remission rate was 15% of fresh FMT for UC and was 42% of frozen FMT for UC (as shown in Table 2). Additionally,

26 cases in the 225 UC were unclear whether fresh or frozen FMT.

For CD patients, 49 patients accepted fresh donor stool FMT in which 24 cases achieved clinical remission, and 45 patients accepted frozen donor stool FMT in which 16 cases achieved clinical remission. The pooled clinical remission rate was 36% of fresh stool FMT for CD and was 28% of frozen stool FMT for CD (as shown in Table 2).

3.2.5. *Route of Administration.* Among the 225 UC patients, 137 patients received FMT via the lower gastrointestinal tract in which 38 cases achieved clinical remission, and 42 patients via the upper gastrointestinal tract in which 6 cases achieved clinical remission. The pooled proportion of clinical remission rate of upper gastrointestinal tract FMT for UC was 8% and 31% of lower gastrointestinal tract FMT for UC. Additionally, 46 UC patients obtained both upper and lower routes FMT (as shown in Table 2).

Among CD patients, 63 patients received FMT via upper gastrointestinal delivery route in which 26 cases achieved clinical remission and 20 patients received lower gastrointestinal route FMT in which 10 cases achieved clinical remission. The pooled proportion of clinical remission rate of upper gastrointestinal tract FMT for CD was 23% and 27% of lower gastrointestinal tract FMT (as shown in Table 2).

TABLE 3: RCTs of FMT in UC.

|                 | Costello et al [41].  | Moayyedi et al [14].  | Paramsothy et al [15].  | Rossen et al [16].    |
|-----------------|-----------------------|-----------------------|-------------------------|-----------------------|
| Number          | 73(38 FMT/35 placebo) | 75(38 FMT/37 placebo) | 81(41 FMT/40 placebo)   | 48(23 FMT/25 placebo) |
| Severity        | mild-moderate         | mild-moderate         | mild-moderate           | mild-moderate         |
| Route           | colonoscopy and enema | enema                 | colonoscopy and enema   | nasoduodenal          |
| Placebo         | Autologous stool      | water                 | water                   | Autologous stool      |
| Donor           | unrelated             | unrelated             | unrelated               | unrelated             |
| Fresh vs Frozen | Frozen                | frozen and fresh      | Frozen                  | Fresh                 |
| Frequency       | 3                     | 6                     | 40(5x/week for 8 weeks) | 2                     |
| Follow-up       | 8 weeks               | 6 weeks               | 8 weeks                 | 12 weeks              |
| Remission       | 12/38(FMT)            | 9/38(FMT)             | 11/41(FMT)              | 7/23(FMT)             |
| FMT/placebo     | 3/35(placebo)         | 2/37(placebo)         | 3/40(placebo)           | 5/25(placebo)         |
| Response        | 21/38(FMT)            | 15/38(FMT)            | 22/41(FMT)              | 11/23(FMT)            |
| FMT/placebo     | 7/35(placebo)         | 9/37(placebo)         | 9/40(placebo)           | 13/25(placebo)        |

### 3.2.6. Meta-Analysis of Disease Severity and Preantibiotic.

Among the 319 patients (UC and CD), 129 patients were described as mild-moderate disease in which 27 cases achieved clinical remission, and 133 patients were defined as moderate-severe disease including 67 refractory patients and 32 hormone-dependent patients in which 45 cases achieved clinical remission. Overall, the pooled proportion of clinical remission rate was 20% of FMT for mild-moderate IBD and was 30% for the moderate-severe IBD (as shown in Table 2). Moderate-severe IBD patients seem to benefit more from FMT treatment than mild-moderate patients significantly ( $P=0.037$ ).

7 cohort studies assessing 85 patients including 69 UC and 16 CD achieved pretreatment with antibiotics prior to FMT. Totally, 29 patients achieved clinical remission and the pooled proportion of clinical remission rate was 25%. The 234 patients without antibiotic pretreatment included 156 UC and 78 CD, in which 64 patients achieved clinical remission after FMT; the pooled estimate clinical remission rate was 28% (as shown in Table 2).

### 3.3. Meta-Analysis of Randomized Controlled Trials.

There were four RCTs of FMT in UC (Table 3), which included a total of 277 patients; 140/277 (51%) patients received donor FMT and 137/277 (49%) received placebo. The placebo was autologous stool or water; the ratio of FMT versus placebo was 1:1. Enrolled patients in the four RCTs were active and mild-moderate UC. Delivery method included colonoscopy followed by enema [15, 41], enema [14], or nasoduodenal tube [16]. Follow-up time ranged from 7 to 12 weeks.

In meta-analysis of the 4 RCTs, the clinical remission was achieved in 39 of 140 (28%) patients in the FMT groups compared with 13 of 137 (9%) patients in the placebo groups. The OR was 3.67 (95% CI: 1.82-7.39,  $P=0.0003$ ), with no statistically significant heterogeneity between studies ( $I^2=0\%$ ) (as shown in supplement Figure 3).

Clinical response was achieved in 69/140(49%) patients who received donor FMT and 38/137 (28%) patients achieved response with placebo (OR: 2.48, 95%CI: 1.18-5.21); heterogeneity was moderate ( $I^2 = 52\%$ ). FMT showed more significant benefits of induction remission in UC than placebo (as shown in supplement Figure 3).

### 3.4. Microbiological Analyses.

At present, there are few studies on the analysis of intestinal microbial community. Most of the studies mainly compared the changes of flora in the fecal samples before and after transplantation and identified the flora by extracting bacterial DNA or sequencing 16S rRNA from stool samples [30]. A range of studies commented on recipient microbiota changes after FMT treatment with increased diversity or richness [29, 34, 38]. Most studies suggested that the changing tendency of flora after FMT tended to the donor. Cui et al. [21] found that most of the bacterial diversity were increased after FMT and showed a trend highly similar to their related donors. Bacterial diversity of a patient was reduced after FMT, but finally it was confirmed that the patient was given antibiotics before and after FMT in this study, and the author considered that the use of antibiotic affected the diversity and composition of fecal microbiota greatly. Brittnacher et al. [37] showed further proof of similarity with the donors appearing in a range from 2-12 weeks, and the largest similarity was 69%, but whether it is consistent with clinical remission is not yet conclusive. Moayyedi et al. [14] found that there was a statistically significant change in microbiota composition with more diversity in the treatment group compared with the placebo group. Donor with a significant microbial enrichment for the family *Lachnospiraceae* and the genera *Ruminococcus* was associated with successful FMT; there was a trend for responders having microbiota that was more similar to the donor than nonresponders, but this did not achieve statistical significance differences. Some studies identified that therapeutic success of FMT in UC had correlation with increased donor microbial diversity. Paramsothy et al. [15] reported that recipient microbial diversity at baseline predicted response to FMT and microbial diversity increased with FMT during 8-week follow-up. Multidonor FMT batches used for the FMT infusions acquired substantially greater microbial diversity compared with the individual donors. The increase of microbial diversity in recipient after FMT in responders was greater than that in nonresponders.

### 3.5. Safety and Adverse Events.

Each of the studies monitored and reported the adverse events after FMT. Majority adverse events were transient gastrointestinal complaints, such as




FIGURE 2: Forest plots of sensitivity analyses.

diarrhea, abdominal pain, bloating, and borborygmus. Fever in varying degrees (with or without chills) was self-limited after FMT. And vomiting, nasal congestion, runny nose, or sore throat occasionally appeared. No serious adverse events were reported. Rare adverse events were also reported. Scaldaferri et al. [24] conducted FMT to eight mild-moderate UC patients; as a result, two patients had worse disease and one patient had unexplained kidney stones after FMT. Vaughn et al. [38] treated 19 CD patients with FMT; urticaria occurred in one patient and remitted after hormone therapy; another patient did not achieve clinical improvement and finally performed surgery eight weeks after FMT.

In general, FMT was well tolerable, safe, and effective in IBD. However, the follow-up time ranged from 1 to 72 months in the present study. There is insufficient data on the long-term efficacy and safety of FMT for IBD at present.

**3.6. Sensitivity Analysis.** Sensitivity analyses were performed, and the results showed no significant change when any one study was excluded (as shown in Figure 2).

Based on the funnel plots of publication bias, there was no evidence of publication bias (Egger’s statistic = 0.78,  $p = 0.45$ ) (as shown in Figure 3).

**4. Discussion**

**4.1. FMT Is an Effective Therapy for IBD.** This study represents an up-to-date meta-analysis study with systematic retrospective and complete cohort study and RCTs properties that can more critically evaluate the efficacy and safety of




FIGURE 3: Funnel plots of publication bias.

FMT on IBD. We identified a total of 596 IBD patients in which 459 patients accept FMT treatment; overall, 28.8% (132/459) of IBD patients achieved clinical remission, and 53% (241/459) of patients achieved clinical response during follow-up.

The treatment effects on patients who have undergone FMT to treat UC appear very promising, especially for patients with multiple infusions administered via the lower gastrointestinal tract. Colman et al. [48] reported a meta-analysis assessing only UC cohort studies, identified 79 patients with a pooled proportion achieving clinical remission of 22% [95% CI: 10.4%-40.8%] in 2014. In 2017, Paramsothy et al. [49] reported a meta-analysis that identified 24 UC cohort studies assessing 307 patients, with a pooled proportion of clinical remission rate of 33% [95% CI: 23%-43%], with a moderate risk of heterogeneity. However, this review primarily included some case reports as well as

cohort studies and RCTs. The present meta-analysis primarily consisted of cohort studies and RCTs, and the subgroup analysis for UC consisted of 23 cohort studies assessing 225 patients with a pooled proportion of clinical remission of 21% (95% CI: 8%-38%), with a high risk of heterogeneity (Cochran's Q,  $P < 0.01$ ,  $I^2 = 88\%$ ).

In meta-analysis of four published RCTs, FMT was significantly more effective than placebo in induction remission of active UC (28% in FMT group versus 9% in placebo groups, OR: 3.67 95% CI: 1.82-7.39,  $P = 0.64$ ,  $I^2 = 0\%$ ), with no significant risk of heterogeneity between studies. FMT was associated with higher combined clinical and endoscopic remission than placebo.

Regarding the role of FMT in CD, previous meta-analysis showed that the pooled proportion of achieved clinical remission rate was 60.5% (95% CI = 28.4%-85.6%) for CD ( $P = 0.05$ ,  $I^2 = 37\%$ ) [48]. Latest meta-analysis showed that the pooled proportion was 52% (95% CI: 31%-72%) for CD, with a moderate risk of heterogeneity [49]. 94 CD patients were enrolled in the current meta-analysis, the pooled proportion of achieved clinical remission was 30% (95% CI: 13%-52%) with a risk of heterogeneity (Cochran's Q,  $P < 0.01$ ,  $I^2 = 75\%$ ), which was lower than that in the previously reported system reviews [16, 41].

There remain major limitations in the available literature of FMT in CD, with the variability of methodology among individual studies and the still limited data; in particular no RCTs data are published to date. Furthermore, unlike UC which is just limited to the mucosal layer, CD usually involves deeper tissues and can be in any region of the gastrointestinal tract. Clinical remission did not correlate with endoscopic outcomes in CD. Efficacy of FMT in CD should be interpreted with caution.

**4.2. FMT May Be More Efficacious in Severe IBD.** Among the 129 mild-moderate IBD patients, 20.9% (27/129) achieved clinical remission, while the clinical remission rate was 32.3% (43/133) in moderate-severe IBD patients. Overall, the pooled proportion of clinical remission rate in mild-moderate patients was 22% (95% CI: 6%-41%, Cochran's Q,  $I^2 = 84\%$ ,  $P < 0.01$ ) with a high risk of heterogeneity, while that in moderate-severe patients was 25% (95% CI: 10%-46%, Cochran's Q,  $I^2 = 83\%$ ,  $P < 0.01$ ). Moderate-severe IBD patients could achieve more significant remission from FMT than mild-moderate patients ( $P = 0.037$ ). These interesting findings indicated that FMT might be a potential rescue therapy for refractory IBD, even expected to be an initial standardized treatment for IBD.

**4.3. Delivery Route Has No Impact on the Efficacy of FMT in IBD.** Common upper GI delivery route is nasogastric tube, nasoduodenal tube, or nasojejenum. Common lower GI delivery route is colonoscopy or rectal enemas. Systematic review of FMT for the treatment of CDI demonstrated that colonoscopic delivery had higher rates of success than that of other delivery methods [50].

The optimal FMT route in IBD is uncertain. In the present study, 61% (137/225) UC patients selected the lower GI tract, 19% (42/225) selected the upper GI tract, and 20% (46/225)

selected both routes. There was an observed trend towards higher clinical resolution rates by lower GI route compared to upper GI route of delivery of FMT in UC [28% (38/137) versus 14%(6/42)]; however no significance was noted in Chi-Squared analysis ( $P = 0.101$ ). According to the present meta-analysis, the rate of clinical remission of FMT for UC was similar via upper or lower GI delivery route, which was consistent with the recently published meta-analysis by Costello et al. [51].

Among the 94 CD patients, 67% (63/94) selected the upper GI tract delivery route, and 21% (20/94) selected the lower GI tract delivery route. The clinical remission rate was 41% (26/63) for upper GI route and 50% (10/20) for lower GI route, and similar results were later obtained from a Chi-Squared analysis with no significance between upper and lower GI delivery method ( $P = 0.492$ ). In addition to efficacy, acceptable delivery method for patient is important to the success of FMT therapy. Delivery route has no impact on the efficacy of FMT in UC and CD; clearly future trials are needed to identify safer, efficacious, and economical mode of FMT delivery.

**4.4. Donor Selection of FMT in IBD.** The optimal donor stool for FMT is still uncertain. In cohorts of patients who have undergone FMT to treat CDI, the choice of donor does not have an important impact on the efficacy of therapy [52]. In the present study, donor stools were from healthy adults or children family members or close friends or volunteers. Among the 319 patients, 134 patients received fecal bacteria from their family members or close friends and 21% (26/134) achieved clinical remission. 79 patients were from healthy anonymous donors, with 37% (29/79) achieving clinical remission. 37 patients were from both family members or friends and healthy volunteers and 69 patients did not report any donor source. This makes it difficult to recommend a particular source of donor and more difficult to analyze the pooled results of the studies. Paramsothy [15] and colleagues tried pooled donor stool FMT in UC, which could provide an increased diversity of microorganisms in the stool suspension than that of a single donor. However, it is not clear whether this theoretical benefit translates to improving the efficacy. Further researches are required to optimize the stool processing, dose of stool, treatment protocols, and so on.

**4.5. Fresh or Frozen Donor Stool Selection of FMT in IBD.** Several studies have compared rates of clinical remission of FMT in treating RCDI with fresh or frozen fecal microbiota. Results showed that neither anaerobic or aerobic stool preparation nor fresh or frozen stool significantly influences the efficacy of FMT in RCDI; frozen FMT had equal effects and risk of adverse events to fresh FMT [53]. Cui et al. [36] reported that fresh fecal microbiota appeared to have higher rate of clinical improvement and clinical remission than that of frozen microbiota for refractory CD, but this research just was a case series. In the present analysis, results were obtained with an observed trend towards higher clinical remission rate of frozen stool FMT than that of fresh stool for UC. Based on current available evidence, the clinical remission rate has no significant difference between fresh and frozen FMT for CD.



However, the number of cases analyzed in this analysis was smaller. Further research must be conducted to determine the most effective, standardized mode of donor stool sample preparation, which will also help in better understanding of its mechanism of action.

A potential mechanism for the observed benefits of FMT in the treatment of IBD is its colonization of the recipient's intestine with donor flora [54]. In RCDI, several studies have compared the microbiota composition before and after FMT and have shown that fecal bacterial composition of the recipient was highly similar to that of the donor and was accompanied by resolution of symptoms [55, 56]. In the present system review, most studies mainly compared the changes of flora in the fecal samples before and after FMT and identified the flora by extracting bacterial DNA or sequencing 16s rRNA from stool samples. The changing tendency of flora in IBD after FMT tends to the donor, with increased diversity or richness.

**4.6. Effects of FMT in Paediatric and Adult IBD.** Up to date, published literatures on the effect of FMT in paediatric IBD were sparse and no randomized controlled trials have been published. In the present meta-analysis, the pooled estimate of clinical remission of FMT for paediatric UC was 10% (95% CI: 0%-43%) and 45% for paediatric CD (95% CI: 24%-66%), while it was 26% (95% CI: 10%-48%) for adult UC and 22% (95% CI=3%-52%) for adult CD.

Compared to adult population, paediatric population has a dynamic developing gut microbiome and Crohn's disease and ulcerative colitis typically have a much more aggressive course in the paediatric age group; paediatric IBD phenotype may have a pathophysiology that is distinct from adult-onset IBD [57].

Compared to adults, here is a paucity of data available in children who may differ from adults for many reasons including having a dynamic developing microbiome compared to adults who have a relatively stable microbiome. Paediatric IBD and the paediatric microbiome have several unique features that suggest that microbial based therapies could be particularly effective.

**4.7. Safety of FMT for IBD.** Generally speaking, FMT was tolerable and safe for IBD. Common reported complications after FMT treatment were fever, abdominal pain, bloating, diarrhea, and other adverse reactions such as nasal congestion, vomiting, and sore throat, most of which were self-limiting, lasting generally no more than 24 h. Even though some complications need drug treatment, they can also ease quickly.

Due to the reported short term follow-up evaluation, long-term safety such as effects on immune function and potential infections and so on still need more clinical trials. Therefore, it is particularly important to strictly screen fecal donor and extraction process of fecal bacteria before FMT. To improve security, many researches recommended the use of feces donated from children, parents, spouses, relatives, and friends of patient who have the same living environment. As the genetic characteristics of IBD and intestinal microbial differ individually, the donor screen needs further investigation.

## 5. Conclusions

FMT is an effective and safe therapy for both paediatric and adult IBD; fresh or frozen donor stool, delivery route, and antibiotic pretreatment or not have no impact on the efficacy of FMT in IBD. FMT might be a potential rescue therapy for refractory IBD and it is even expected to be an initial standardized therapy for IBD. However, there is insufficient data on the long-term efficacy and safety of FMT in IBD at present. Further researches, especially the RCT study, are needed to identify safer, efficacious, and economical method of FMT and its potential mechanism.

## Disclosure

No data have been fabricated or manipulated (including images) to support the conclusions. No data, text, or theories by others are presented without indicating quotation marks.

## Conflicts of Interest

The authors have no financial or potential conflicts of interest or affiliation with any institution, organization, or company relating to the manuscript.

## Authors' Contributions

All authors have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results. All authors have read the manuscript and approved submitting to the journal. Haiming Fang and Jiajia Wang designed the study; Haiming Fang, Lian Fu, and Jiajia Wang collected, analyzed, and interpreted the data and drafted the article; Jiajia Wang critically revised the manuscript for important intellectual content. Haiming Fang and Jiajia Wang contributed equally to this study and were co-corresponding author.

## Acknowledgments

This research was supported by the doctoral fund of the second hospital of Anhui Medical University (NO. 2012BKJ004) and the clinical backbone grants of the second hospital of Anhui Medical University. All authors thank sincerely Professor Haifeng Pan and Yanmei Mao for their kind help in the data statistics.

## Supplementary Materials

Supplement-Figure 1: Forest plot for the pooled proportion of remission of FMT for IBD patients in cohort studies. Supplement-Figure 2: Forest plot for the pooled proportion of remission of FMT for UC (2a) and CD (2b) patients in cohort studies. Supplement-Figure 3: Forest plot for clinical remission (3a) and clinical response (3b) of FMT for UC patients in randomized controlled trials. (*Supplementary Materials*)

## References

- [1] E. van Nood, A. Vrieze, and M. Nieuwdorp, "Duodenal infusion of donor feces for recurrent clostridium difficile," *The New England Journal of Medicine*, vol. 368, no. 5, pp. 407-415, 2013.

- [2] R. B. Sartor, "Microbial influences in inflammatory bowel diseases," *Gastroenterology*, vol. 134, no. 2, pp. 577–594, 2008.
- [3] J. M. Yi and T. O. Kim, "Epigenetic alterations in inflammatory bowel disease and cancer," *Intestinal Research*, vol. 13, no. 2, pp. 112–121, 2015.
- [4] H. Chu, A. Khosravi, I. P. Kusumawardhani et al., "Genemicrobiota interactions contribute to the pathogenesis of inflammatory bowel disease," *Science*, vol. 352, no. 6289, pp. 1116–1120, 2016.
- [5] D. Knights, M. S. Silverberg, R. K. Weersma et al., "Complex host genetics influence the microbiome in inflammatory bowel disease," *Genome Medicine*, vol. 6, no. 12, article 107, 2014.
- [6] F. Zhang, W. Luo, Y. Shi, Z. Fan, and G. Ji, "Should we standardize the 1,700-year-old fecal microbiota transplantation?" *American Journal of Gastroenterology*, vol. 107, no. 11, pp. 1755–1755, 2012.
- [7] B. Eiseman, W. Silen, G. S. Bascom, and A. J. Kauvar, "Fecal enema as an adjunct in the treatment of pseudomembranous," *Surgery*, vol. 44, no. 5, pp. 854–859, 1958.
- [8] D. Drekonja, J. Reich, S. Gezahegn et al., "Fecal microbiota transplantation for clostridium difficile infection a systematic review," *Annals of Internal Medicine*, vol. 162, no. 9, pp. 630–638, 2015.
- [9] C. M. Surawicz, L. J. Brandt, D. G. Binion et al., "Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections," *American Journal of Gastroenterology*, vol. 108, no. 4, pp. 478–498, 2013.
- [10] S. B. Debast, M. P. Bauer, E. J. Kuijper et al., "European society of clinical microbiology and infectious diseases: update of the treatment guidance document for *Clostridium difficile* infection," *Clinical Microbiology and Infection*, vol. 20, no. 2, pp. 1–26, 2014.
- [11] J. D. Bennet and M. Brinkman, "Treatment of ulcerative colitis by implantation of normal colonic flora," *The Lancet*, vol. 333, no. 8630, p. 164, 1989.
- [12] D. Sun, W. Li, S. Li et al., "Fecal microbiota transplantation as a novel therapy for ulcerative colitis: A systematic review and meta-analysis," *Medicine*, vol. 95, no. 23, 2016.
- [13] Y. Shi, Y. Dong, W. Huang et al., "Fecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis," *PLoS ONE*, vol. 11, no. 6, 2016.
- [14] P. Moayyedi, M. G. Surette, P. T. Kim et al., "Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial," *Gastroenterology*, vol. 149, no. 1, pp. 102–109, 2015.
- [15] S. Paramsothy, M. A. Kamm, N. O. Kaakoush et al., "Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial," *The Lancet*, vol. 389, no. 10075, pp. 1218–1228, 2017.
- [16] N. G. Rossen, S. Fuentes, M. J. Van Der Spek et al., "Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis," *Gastroenterology*, vol. 149, no. 1, pp. 110–118, 2015.
- [17] Z. Kassam, C. H. Lee, Y. Yuan, and R. H. Hunt, "Fecal microbiota transplantation for clostridium difficile infection: systematic review and meta-analysis," *American Journal of Gastroenterology*, vol. 108, no. 4, pp. 500–508, 2013.
- [18] S. Angelberger, W. Reinisch, A. Makrithatis et al., "Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation," *American Journal of Gastroenterology*, vol. 108, no. 10, pp. 1620–1630, 2013.
- [19] S. Kunde, A. Pham, S. Bonczyk et al., "Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 56, no. 6, pp. 597–601, 2013.
- [20] P. K. Kump, H.-P. Gröchenig, S. Lackner et al., "Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis," *Inflammatory Bowel Diseases*, vol. 19, no. 10, pp. 2155–2165, 2013.
- [21] B. Cui, P. Li, and L. Xu, "Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis," *Journal of Translational Medicine*, vol. 13, no. 298, 2015.
- [22] C. J. Damman, M. J. Brittnacher, M. Westerhoff et al., "Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis," *PLoS ONE*, vol. 10, no. 8, 2015.
- [23] R. Ren, G. Sun, Y. Yang et al., "A pilot study of treating ulcerative colitis with fecal microbiota transplantation," *Chinese Journal of Internal Medicine*, vol. 54, no. 5, pp. 411–415, 2015.
- [24] F. Scaldaferrri, S. Pecere, G. Bruno et al., "An Open-label, pilot study to assess feasibility and safety of fecal microbiota transplantation in patients with mild-moderate ulcerative colitis: preliminary results," *Journal of Crohn's and Colitis*, vol. 9, 2015.
- [25] Y. Wei, W. Zhu, J. Gong et al., "Fecal microbiota transplantation improves the quality of life in patients with inflammatory bowel disease," *Gastroenterology Research and Practice*, vol. 2015, Article ID 517597, 5 pages, 2015.
- [26] D. L. Suskind, N. Singh, H. Nielson, and G. Wahbeh, "Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 60, no. 1, pp. 27–29, 2015.
- [27] S. Vermeire, M. Joossens, K. Verbeke et al., "Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease," *Journal of Crohn's and Colitis*, vol. 10, no. 4, pp. 387–394, 2016.
- [28] A. Nishida, H. Imaeda, M. Ohno et al., "Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis," *Journal of Gastroenterology*, vol. 52, no. 4, pp. 476–482, 2017.
- [29] Y. Wei, J. Gong, W. Zhu et al., "Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora," *BMC Microbiology*, vol. 16, no. 1, pp. 1–9, 2016.
- [30] D. Ishikawa, T. Sasaki, T. Osada et al., "Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis," *Inflammatory Bowel Diseases*, vol. 23, no. 1, pp. 116–125, 2017.
- [31] T. Zhang, B. Cui, P. Li et al., "Short-term surveillance of cytokines and C-reactive protein cannot predict efficacy of fecal microbiota transplantation for ulcerative colitis," *PLoS One*, vol. 11, no. 6, 2016.
- [32] T. Karakan, M. Ibis, Z. Cindoruk et al., "Faecal microbiota transplantation as a rescue therapy for steroid-dependent and/or non-responsive patients with ulcerative colitis: a pilot study," in *Proceedings of the 11th Congress of the European Crohn's and Colitis Organisation (ECCO '16)*, p. P639, Amsterdam, The Netherlands, 2016.
- [33] A. Goyal, A. Chu, K. Calabro et al., "Safety and efficacy of fecal microbiota transplant in children with inflammatory bowel disease," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 63, p. S212, 2016.

- [34] R. Kellermayer, D. Nagy-Szakai, R. A. Harris et al., "Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis," *American Journal of Gastroenterology*, vol. 110, no. 4, pp. 604–606, 2015.
- [35] K. Karolewska-Bochenek, I. Lazowska-Przeorek, P. Grzesiowski et al., "Fecal microbiota transplantation in refractory pediatric UC - Preliminary data," *Journal of Crohn's and Colitis*, vol. 9, supplement 1, p. S294, 2015.
- [36] B. Cui, Q. Feng, H. Wang et al., "Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility and efficacy trial results," *Journal of Gastroenterology and Hepatology*, vol. 30, no. 1, pp. 51–58, 2015.
- [37] D. L. Suskind, M. J. Brittnacher, G. Wahbeh et al., "Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease," *Inflammatory Bowel Diseases*, vol. 21, no. 3, pp. 556–563, 2015.
- [38] B. P. Vaughn, T. Vatanen, J. R. Allegretti et al., "Increased intestinal microbial diversity following fecal microbiota transplant for active crohn's disease," *Inflammatory Bowel Diseases*, vol. 22, no. 9, pp. 2182–2190, 2016.
- [39] F. M. Zhang, H. G. Wang, M. Wang et al., "Standard fecal microbiota transplantation through mid-gut is an effective therapy of refractory Crohn's disease," *Journal of Gastroenterology and Hepatology*, vol. 28, no. 9, 2013.
- [40] A. Goyal, A. Yeh, B. R. Bush et al., "Safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease," *Inflammatory Bowel Diseases*, vol. 24, no. 2, pp. 410–421, 2018.
- [41] S. P. Costello, O. Waters, R. V. Bryant et al., "Short duration, low intensity, pooled fecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial," *Gastroenterology*, vol. 152, no. 5, pp. S198–S199, 2017.
- [42] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," *British Medical Journal*, vol. 339, article b2535, 2009.
- [43] A. D. Furlan, V. Pennick, C. Bombardier, and M. van Tulder, "2009 Updated method guidelines for systematic reviews in the cochrane back review group," *The Spine Journal*, vol. 34, no. 18, pp. 1929–1941, 2009.
- [44] D. F. Stroup, J. A. Berlin, S. C. Morton et al., "Meta-analysis of observational studies in epidemiology: a proposal for reporting," *Journal of the American Medical Association*, vol. 283, no. 15, pp. 2008–2012, 2000.
- [45] G. Wells, B. Shea, D. O'Connell et al., "The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses," vol. 2017, [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
- [46] J. P. T. Higgins, D. G. Altman, P. C. Gøtzsche et al., "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials," *British Medical Journal*, vol. 343, no. 7829, 2011.
- [47] J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in a meta-analysis," *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.
- [48] R. J. Colman and D. T. Rubin, "Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis," *Journal of Crohn's and Colitis*, vol. 8, no. 12, pp. 1569–1581, 2014.
- [49] S. Paramsothy, R. Paramsothy, D. T. Rubin et al., "Faecal microbiota transplantation for inflammatory bowel disease: A systematic review and meta-analysis," *Journal of Crohn's and Colitis*, vol. 11, no. 10, pp. 1180–1199, 2017.
- [50] G. Cammarota, G. Ianiro, and A. Gasbarrini, "Fecal microbiota transplantation for the treatment of clostridium difficile infection: A systematic review," *Journal of Clinical Gastroenterology*, vol. 48, no. 8, pp. 693–702, 2014.
- [51] S. P. Costello, W. Soo, R. V. Bryant, V. Jairath, A. L. Hart, and J. M. Andrews, "Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis," *Alimentary Pharmacology & Therapeutics*, vol. 46, no. 3, pp. 213–224, 2017.
- [52] M. Osman, Z. Stoltzner, K. O'Brien et al., "Donor efficacy in fecal microbiota transplantation for recurrent clostridium difficile: evidence from a 1,999-patient cohort," *Open Forum Infectious Diseases*, vol. 3, supplement 1, 2016.
- [53] M. J. Hamilton, A. R. Weingarden, M. J. Sadowsky, and A. Khoruts, "Standardized frozen preparation for transplantation of fecal microbiota for recurrent *Clostridium difficile* infection," *American Journal of Gastroenterology*, vol. 107, no. 5, pp. 761–767, 2012.
- [54] T. J. Borody and A. Khoruts, "Fecal microbiota transplantation and emerging applications," *Nature Reviews Gastroenterology & Hepatology*, vol. 9, no. 2, pp. 88–96, 2012.
- [55] A. Khoruts, J. Dicksved, J. K. Jansson, and M. J. Sadowsky, "Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent clostridium difficile-associated diarrhea," *Journal of Clinical Gastroenterology*, vol. 44, no. 5, pp. 354–360, 2010.
- [56] M. Girotra, S. Garg, R. Anand, Y. Song, and S. K. Dutta, "Fecal microbiota transplantation for recurrent clostridium difficile infection in the elderly: long-term outcomes and microbiota changes," *Digestive Diseases and Sciences*, vol. 61, no. 10, pp. 3007–3015, 2016.
- [57] A. Y. Wang, J. Popov, and N. Pai, "Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease," *World Journal of Gastroenterology*, vol. 22, no. 47, pp. 10304–10315, 2016.



**Hindawi**

Submit your manuscripts at  
[www.hindawi.com](http://www.hindawi.com)

